Login to Your Account



ACT Carries Torch for hESC Therapies Post-Geron Exit

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 23, 2011
Advanced Cell Technology Inc. (ACT) is about to deliver good news from its Phase I/II trials of retinal pigmented epithelial (RPE) cells and perk up the prospects for human embryonic stem cell (hESC)-based therapies following Geron Inc.'s abrupt withdrawal from the field last week.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription